Bulletin Updates
Granules Q1 hit by USFDA halt – 12 Aug 2025
Aug 12, 2025
Granules India’s Q1 profit fell as USFDA-linked production pause dented sales
Revenue stayed flat despite higher consultant and freight costs
Extra costs from a buyout and settlements also weighed on earnings
The full story is for subscribers. Log in to read it, or start a free trial.
Log in Start a free trial »
Log in Start a free trial »